Sandra Beaver

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, has appointed Sandra Beaver to its Board of Directors.

Beaver joins the Board as an independent director and will serve on both the Audit Committee and the Cybersecurity and Data Oversight Committee, further strengthening the company’s financial and governance expertise.

Sandra Beaver brings more than 20 years of global strategic and operational finance experience across a wide range of industries, including healthcare, medical devices, enterprise technology, gaming, and manufacturing. Her background combines financial leadership with deep operational insight, making her a valuable addition as Tandem continues to scale its technology-driven diabetes care solutions.

Beaver currently serves as Chief Financial Officer of Lyra Health, a leading provider of mental health solutions, where she oversees finance, accounting, investor relations, facilities, procurement, and corporate development. She assumed this role in June 2025, supporting Lyra’s growth and operational maturity in a rapidly evolving healthcare landscape. Prior to Lyra Health, Beaver served as Chief Financial Officer of Evolus, a publicly traded medical aesthetics company, where she led financial strategy and operations for three years.

Earlier in her career, Beaver held senior finance leadership roles at Experian, a global data and technology company, and at IGT, a global gaming and technology organization. Across these roles, she developed strong expertise in financial governance, risk management, and supporting technology-enabled business models.

Beaver holds a Bachelor of Business Administration from the University of Massachusetts and a professional designation in Relational Database Design from UCLA. Her appointment reflects Tandem Diabetes Care’s continued focus on strong corporate governance, financial discipline, and cybersecurity oversight as the company advances innovation in diabetes management.